Navigation Links
Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
Date:6/22/2011

NUTLEY, N.J. and BASEL, Switzerland, June 22, 2011 /PRNewswire/ -- The Roche manuscript: "Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies" has been published in the prestigious Proceedings of the National Academy of Sciences of the USA (PNAS). Corresponding authors are Wolfgang Schaefer, Research Leader Molecular Biology in Biologics Research at Penzberg, and Christian Klein, Head of Oncology Programs, Discovery Oncology at Roche Glycart. Both are part of Roche's Pharma Research and Early Development (pRED) organization.  

"It is encouraging to us that PNAS reviewers recognized the novelty of the approach for the generation of human bispecific, bivalent antibodies," note Wolfgang Schaefer and Christian Klein. "This technological breakthrough from pRED allowing generation and production of bispecific bivalent IgG antibodies that are very similar to conventional IgGs will prove a formidable benefit to patients."

The published paper describes a novel and generic approach to convert two given antibodies to human bivalent bispecific IgG antibodies that behave like standard monoclonal IgG antibodies in terms of target binding, stability and pharmacokinetics.

"Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies", PNAS online Early Edition (EE), http://www.pnas.org/content/early/recent.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
2. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
3. REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)
4. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
5. Ikaria® To Present at 2011 BIO Business Forum and International Convention
6. Most Expensive Teas in the World Worth US$44,500 per 4 Ounces Each are Positioned for International Distribution Says Protein Reactor Combined Fuels Inc (OTC: PRCF) Founder Chairman and CEO Nestor C. Buenaflor
7. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
8. Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes
9. MacuCLEAR, Inc. to Present at OneMedForum New York 2011 and at the 2011 BIO Business Forum During the Annual BIO International Convention in Washington, D.C.
10. NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society
11. BioXpress Therapeutics SA to Partner the 2011 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... (March ... International Mexico has been approved as an active member of the Mexican ... protection among distributers and consumers in relationship marketing. This professional organization fosters loyal ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... instrumentation for cell-based assays, disperses a quarterly travel award to noteworthy scientists who ... the company announced that its new round of awards are being given to ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - The University of ... Nordion, a business of Sterigenics International, and General Atomics ... been submitted to the U.S. Nuclear Regulatory Commission (NRC). ... production of molybdenum-99 (Mo-99). Once operational, production from this ... U.S. demand for Mo-99, which currently must be imported ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... NetDimensions Learning to replace paper-based processes and enhance training plan management for consistent ... very pleased to partner with the SHL Group to help improve and streamline ...
Breaking Biology Technology:
(Date:2/21/2017)... and PORTLAND, Ore. , Feb. 22, ... Avamere Family of Companies (Avamere Health Services, Infinity Rehab, ... six-month research study that will apply the power of ... senior living and health centers. By analyzing data streaming ... gain insights into physical and environmental conditions, and obtain ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
Breaking Biology News(10 mins):